Mazdutide
Dual GLP-1/Glucagon Receptor Agonist | Weight Reduction & Diabetes
On this page
What is Mazdutide?
Mazdutide is a lab-made peptide modeled on a natural gut hormone called oxyntomodulin, engineered to activate two receptors (GLP-1 and glucagon) at once, which is why it's called a dual agonist. It's an investigational compound studied in Phase 3 trials for metabolic and diabetes research, not yet an FDA-approved medication. Research-grade mazdutide sold here is intended for laboratory research use only, it is not the same product as, and is not a substitute for, an approved medication.
Key terms:
Mazdutide is a dual glp-1/glucagon receptor agonist (synthetic oxyntomodulin analog with fatty-acid conjugation).
Mazdutide (IBI362/LY3305677) is a lab-made version of oxyntomodulin, a natural gut hormone. It was the first of its kind to act on two receptors at once: GLP-1 (a gut hormone that influences appetite and blood sugar) and glucagon (which affects how the body burns energy). Tirzepatide, by contrast, targets GIP and GLP-1. Researchers study the GLP-1 side for reduced appetite and the glucagon side for raising heat production and energy use. The Phase 3 GLORY-1 and GLORY-2 trials reported up to 20% weight reduction. Recent head-to-head trials reported greater effects than semaglutide on blood-sugar control and weight reduction in participants with type 2 diabetes and obesity.
Key research areas
- Up to 20% body weight reduction
- Greater glycemic control reported vs semaglutide in trials
- Increased energy expenditure via glucagon receptor activation
- Improved cardiometabolic markers (BP, lipids, liver fat)
- Once-weekly convenience
Researched dosing
This table reflects how researchers structure mazdutide study designs, the titration schedules and dose ranges used in published trials, presented as research methodology, not personal usage guidance.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Weight-reduction studies (3 mg step) | 1.5mg → 3mg | Once weekly | SubQ injection |
| Weight-reduction studies (4.5 mg step) | 1.5mg → 3mg → 4.5mg | Once weekly | SubQ injection |
| Weight-reduction studies (6 mg step) | 2mg → 4mg → 6mg | Once weekly | SubQ injection |
| Weight-reduction studies (9 mg step) | 3mg → 6mg → 9mg | Once weekly | SubQ injection |
| Type 2 diabetes studies (mild-moderate) | 3-4.5mg weekly | Once weekly | SubQ injection |
| Type 2 diabetes with obesity studies | 6-9mg weekly | Once weekly | SubQ injection |
Commonly cycled 60 weeks on, 0+ weeks off.
How it works
At the cell level, mazdutide research looks at how the peptide binds both GLP-1 and glucagon receptors to influence insulin release, digestion speed, and energy expenditure, the terms below are just the names for those cell-signaling steps.
Dual agonist of GLP-1 and glucagon receptors. GLP-1 activation: stimulates insulin release, suppresses glucagon, slows gastric emptying, reduces appetite via hypothalamic signaling. Glucagon activation: increases energy expenditure and thermogenesis, improves hepatic fat metabolism. The dual mechanism provides synergistic weight reduction effects while GLP-1 counteracts glucagon's glucose-raising effects.
Molecular data
These figures, molecular weight, amino-acid sequence, chain length, are the chemistry basics researchers use to confirm a mazdutide sample's identity and purity before it goes into a study.
- Weight
- 4563.1 Da
- Length
- 33 amino acids
- Type
- Oxyntomodulin analog with fatty acid conjugation
33-amino acid linear synthetic peptide conjugated to C20 fatty diacid moiety through hydrophilic linker at Lys20
Research applications
This section lists the research areas, metabolic and diabetes research chief among them, that scientists have studied for mazdutide in Phase 3 trial literature; research-grade mazdutide sold here is intended for laboratory study only, not human use.
Weight Reduction
GLORY-2 trial: 20.1% weight reduction with 9mg dose over 60 weeks. 48.7% of non-diabetic participants achieved ≥20% weight reduction - approaching surgical outcomes. Significant reductions in waist circumference, systolic BP (-7.57 mmHg), diastolic BP (-2.98 mmHg), triglycerides (-43%), LDL cholesterol, and uric acid. Exploratory analysis from GLORY-1 showed 80.2% reduction in liver fat content, suggesting potential MASLD/MASH benefits.
Diabetes
Greater glycemic control reported in head-to-head DREAMS-3 trial vs semaglutide: 48.0% vs 21.0% achieved HbA1c <7.0% AND ≥10% weight reduction. Mean HbA1c reduction -2.03% vs -1.84%.
Cardiovascular
Significant reductions in blood pressure and cardiometabolic markers. Increased heart rate (5-17 bpm) observed but not associated with cardiac events in trials.
Dosage reference
- Doses used in research
- Published trials started at 1.5-3 mg weekly, raising the dose about once a month toward the maintenance dose.
- Frequency in studies
- Same day each week, any time of day
- Handling
- Reconstituted solution, research use only; not for administration
- Timeline reported in studies
- Appetite reduction 1-3 days, weight reduction begins 2-4 weeks, significant results 12-24 weeks, peak effects 48-60 weeks
- Storage
- Lyophilized: -20°C long-term; Reconstituted: 2-8°C use within 30 days
- Cycle length
- 48-60+ weeks for full metabolic benefits based on clinical trials
- Break between cycles
- Medical supervision required - effects diminish gradually after discontinuation
Interactions
This list shows which other metabolic-research peptides scientists study alongside mazdutide, and flags pairings that call for extra caution or monitoring in a research setting.
Reconstitution & storage
This is the standard laboratory method for turning freeze-dried mazdutide powder into a liquid research solution, the same basic water-based mixing process used for most peptide research.
- Remove mazdutide vial from freezer/refrigerator and allow to reach room temperature (15-20 minutes)
- Clean vial top with alcohol swab using circular motion, allow to air dry completely
- Calculate appropriate reconstitution volume based on desired concentration
- Draw calculated amount of bacteriostatic water into syringe, remove air bubbles
- Insert needle at 45-degree angle against vial wall, NOT directly into powder
- Slowly inject BAC water down the side of the vial - drop by drop to prevent foaming
- Remove needle and gently swirl vial in circular motion - NEVER shake vigorously
- Allow solution to sit 2-3 minutes if cloudiness persists, then swirl gently until completely clear
- Final solution should be completely clear and colorless - discard if cloudy or contains particles
- Label vial with reconstitution date and concentration
Lyophilized: -20°C long-term, use within Per manufacturer expiration
Reconstituted: 2-6°C, use within 30 days
Open the Mazdutide reconstitution calculatorQuality indicators
These are the visual and lab-report checks researchers use to confirm a mazdutide sample is pure and correctly identified before it goes into a study, a quick sanity check against the Certificate of Analysis (COA), not a guarantee.
White to off-white lyophilized powder - Properly freeze-dried mazdutide appears as light, fluffy powder without clumping or discoloration
Clear reconstituted solution - Should be completely clear and colorless after proper reconstitution - no visible particles
Intact vial seal and labeling - Rubber stopper intact, clear mg dosage, batch numbers, and expiration dates visible
Proper storage conditions maintained - Stored at correct temperature, protected from light, no freeze-thaw cycles
Source verification - Mazdutide is primarily available from research chemical suppliers. Verify purity testing and source reputation
Clumping, discoloration, or moisture - Powder should not be clumped, yellow/brown colored, or show signs of moisture damage
Persistent cloudiness or particles - Cloudiness or visible particles after proper reconstitution indicates degradation - do not use
What to expect
This timeline reflects what the Phase 3 trial literature reports at each study stage, research context for comparing studies, not a personal-results promise.
Trials reported reduced appetite and smaller portion sizes, with mild nausea
Trials reported early weight reduction (1-2%) and improved post-meal satiety
Dose-escalation phase in the trials; GI symptoms improved and weight reduction reached 3-5%
Trials reported steady weight reduction (7-12%) with measurable energy-expenditure effects
Trials reported weight reduction of 12-17% with improving metabolic markers
Peak trial-reported effects (up to 20% weight reduction) with sustained improvement in blood pressure, lipids, and glucose
Safety notes
This section summarizes mazdutide's regulatory status and handling notes, it remains an investigational compound with no FDA approval, and this context is provided for laboratory researchers, not medical guidance.
- Not recommended during pregnancy or breastfeeding - insufficient safety data
- Caution with personal/family history of medullary thyroid carcinoma or MEN2 syndrome
- If taking insulin or sulfonylureas, monitor blood glucose closely and reduce doses as needed
- Monitor for signs of pancreatitis - severe persistent abdominal pain radiating to back
- Not FDA-approved - investigational drug in Phase 3 clinical trials
Regulatory status
- Not approved by the FDA for any indication.
- Supplied and described for laboratory research use only, not for human or veterinary use.
Frequently asked questions
What is Mazdutide?
Mazdutide (IBI362/LY3305677) is a lab-made peptide modeled on a natural gut hormone called oxyntomodulin, engineered to activate two receptors at once, GLP-1 and glucagon, which is why researchers call it a dual agonist. It is an investigational compound studied in Phase 3 trials rather than an approved medication. Lux BioPure supplies research-grade mazdutide strictly for laboratory study, not for use in people or animals.
What class of compound is mazdutide?
Mazdutide is classified as a synthetic oxyntomodulin analog with fatty-acid conjugation that acts as a dual GLP-1 and glucagon receptor agonist. In the research literature it is described as a 33-amino-acid linear peptide with a molecular weight near 4,563 daltons, figures lab technicians use to confirm a sample's identity and purity before it enters a study.
How is mazdutide typically reconstituted for research use?
In the laboratory, a mazdutide vial is brought to room temperature and its top cleaned with an alcohol swab. Bacteriostatic water is injected drop by drop down the vial wall, not onto the powder, to prevent foaming, then the vial is gently swirled, never shaken, until the solution is completely clear and colorless. This is standard peptide-handling methodology, not a usage instruction.
How should mazdutide be stored in the lab?
Lyophilized mazdutide is best held at around -20°C for long-term storage, protected from light and kept free of freeze-thaw cycles. Once reconstituted with bacteriostatic water, the solution is refrigerated near 2-6°C and typically used within about 30 days, with the vial labeled by date and concentration. A good sample is a white, fluffy powder that yields a clear, colorless solution.
Is mazdutide legal to purchase for research in Canada?
Lux BioPure sells mazdutide in Canada strictly as a research-use-only chemical for laboratory study, it is not for human or veterinary use and is not offered as a drug or supplement. Mazdutide is not FDA-approved; it remains an investigational drug in Phase 3 clinical trials, and the research-grade material here is not a substitute for an approved medication.
References
First Phase 3 weight management trial showing clinically meaningful weight reductions with once-weekly mazdutide. Both doses achieved significant weight reduction vs placebo with favorable safety profile.
View StudyHigh-dose 9mg mazdutide achieved 20.1% weight reduction in non-diabetic participants vs 2.8% placebo. 48.7% achieved ≥20% weight reduction. No plateau observed through week 60.
View StudyMazdutide outperformed semaglutide on the primary endpoint - 48.0% vs 21.0% achieved HbA1c <7.0% AND ≥10% weight reduction (p<0.0001). Mean HbA1c reduction -2.03% vs -1.84%.